在厄立特里亚,阿尔特米西宁耐药HRP2-阴性疟疾的患病率不断增加

Selam Mihreteab¹, Lucien Platon¹, Araia Berhane¹+13

• ¹From the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).